1. Vavricka, SR, Schoepfer, A, Scharl, M, Lakatos, PL, Navarini, A, Rogler, G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982–1992.
2. Kim, ER, Chang, DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol 2014;20:9872–9881.
3. Lennard-Jones, JE. Classification of inflamm bowel disease. Scand J Gastroenterol 1989;24(Suppl. 170):2–6.
4. Baumgart, DC, Sandborn, WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641–1657.
5. Lonnfors, S, Vermeire, S, Greco, M, Hommes, D, Bell, C, Avedano, L. IBD and health-related quality of life – discovering the true impact. J Crohns Colitis 2014;8:1281–1286.
6. Johnston, RD, Logan, RF. What is the peak age for onset of IBD? Inflamm Bowel Dis 2008;14(Suppl. 2):S4–S5.
7. Carter, MJ, Lobo, AJ, Travis, SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl. 5):v1–v16.
8. Mowat, C, Cole, A, Windsor, A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.
9. Hwang, JM, Varma, MG. Surgery for inflammatory bowel disease. World J Gastroenterol 2008;14:2678–2690.
10. Sica, GS, Biancone, L. Surgery for inflammatory bowel disease in the era of laparoscopy. World J Gastroenterol 2013;19:2445–2448.
11. Card, T, Hubbard, R, Logan, RFA. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003;125:1583–1590.
12. Straker, M. Ulcerative colitis: recovery of a patient with brief psychiatric treatment. Can Med Assoc J 1960;82:1224–1227.
13. Daniels, GE. Psychiatric aspects of ulcerative colitis. N Engl J Med 1942;226:178–184.
14. Sullivan, AJ, Chandler, CA. Ulcerative colitis of psychogenic origin: a report of six cases. Yale J Biol Med 1932;4:779–796.
15. Murray, CD. Psychogenic factors in the etiology of ulcerative colitis and bloody diarrhea. Am J Med Sci 1930;180:239–247.
16. Farrokhyar, F, Marshall, JK, Easterbrook, B, Irvine, EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006;12:38–46.
17. Guthrie, E, Jackson, J, Shaffer, J, Thompson, D, Tomenson, B, Creed, F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn’s disease. Am J Gastroenterol 2002;97:1994–1999.
18. Addolorato, G, Capristo, E, Stefanini, GF, Gasbarrini, G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997;32:1013–1021.
19. Mikocka-Walus, A, Knowles, SR, Keefer, L, Graff, L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis 2016;22:752–762.
20. Gandhi, S, Jedel, S, Hood, MM, Mutlu, E, Swanson, G, Keshavarzian, A. The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. J Crohns Colitis 2014;8:401–408.
21. Goodhand, JR, Wahed, M, Mawdsley, JE, Farmer, AD, Aziz, Q, Rampton, DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis 2012;18:2301–2309.
22. Addolorato, G, Mirijello, A, D’Angelo, C et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. Int J Clin Pract 2008;62:1063–1069.
23. Calvet, X, Gallardo, O, Coronas, R et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s disease. Inflamm Bowel Dis 2006;12:692–696.
24. Clark, JG, Srinath, AI, Youk, AO et al. Predictors of depression in youth with Crohn disease. J Pediatr Gastroenterol Nutr 2014;58:569–573.
25. Bokemeyer, B, Hardt, J, Huppe, D et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 2013;7:355–368.
26. Ben Thabet, J, Charfi, N, Mnif, L et al. Emotional disorders and inflammatory bowel disease. Tuni Med 2012;90:557–563.
27. Cawthorpe, D, Davidson, M. Temporal comorbidity of mental disorder and ulcerative colitis. Perm J 2015;19:52–57.
28. Horst, S, Chao, A, Rosen, M et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. Dig Dis Sci 2015;60:465–470.
29. Keeton, RL, Mikocka-Walus, A, Andrews, JM. Concerns and worries in people living with inflammatory bowel disease (IBD): a mixed methods study. J Psychosom Res 2015;78:573–578.
30. Kinsinger, SW, Ballou, S, Keefer, L. Snapshot of an integrated psychosocial gastroenterology service. World J Gastroenterol 2015;21:1893–1899.
31. Long, MD, Kappelman, MD, Martin, CF, Chen, W, Anton, K, Sandler, RS. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis 2014;8:113–119.
32. Maconi, G, Gridavilla, D, Vigano, C et al. Perianal disease is associated with psychiatric co-morbidity in Crohn’s disease in remission. Int J Colorectal Dis 2014;29:1285–1290.
33. Szigethy, E, Bujoreanu, SI, Youk, AO et al. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry 2014;53:726–735.
34. Szigethy, EM, Youk, AO, Benhayon, D et al. Depression subtypes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;58:574–581.
35. Virta, LJ, Kolho, KL. Antidepressant use among paediatric patients with recent-onset inflammatory bowel disease: a nationwide case control study in Finland. J Paediatr Child Health 2014;50:562–565.
36. Vlachos, II, Barbatis, C, Tsopanomichalou, M et al. Correlation between depression, anxiety, and polymorphonuclear cells’ resilience in ulcerative colitis: the mediating role of heat shock protein 70. BMC Gastroenterol 2014;14:77.
37. Ananthakrishnan, AN, Khalili, H, Pan, A et al. Association between depressive symptoms and incidence of Crohn’s disease and ulcerative colitis: results from the Nurses’ Health Study. Clin Gastroenterol Hepatol 2013;11:57–62.
38. Guloksuz, S, Wichers, M, Kenis, G et al. Depressive symptoms in Crohn’s disease: relationship with immune activation and tryptophan availability. PloS One 2013;8:e60435.
39. Knowles, SR, Wilson, J, Wilkinson, A et al. Psychological well-being and quality of life in Crohn’s disease patients with an ostomy: a preliminary investigation. J Wound Ostomy Continence Nurs 2013;40:623–629.
40. Langhorst, J, Hofstetter, A, Wolfe, F, Hauser, W. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis 2013;19:2380–2386.
41. Schuman, SL, Graef, DM, Janicke, DM, Gray, WN, Hommel, KA. An exploration of family problem-solving and affective involvement as moderators between disease severity and depressive symptoms in adolescents with inflammatory bowel disease. J Clin Psychol Med Settings 2013;20:488–496.
42. Selinger, CP, Lal, S, Eaden, J et al. Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. J Crohns Colitis 2013;7:e214–e218.
43. Shiga, H, Miyazawa, T, Kinouchi, Y et al. Life-event stress induced by the Great East Japan Earthquake was associated with relapse in ulcerative colitis but not Crohn’s disease: a retrospective cohort study. BMJ Open 2013;3:e002294.
44. Besharat, S, Amiriani, T, Roshandel, G, Besharat, M, Semnani, S, Kamkar, M. Depressive mood and disease activity in inflammatory bowel disease. Arab Journal Gastroenterol 2012;13:136–138.
45. Goodhand, JR, Greig, FI, Koodun, Y et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. Inflamm Bowel Dis 2012;18:1232–1239.
46. Loftus, EV Jr., Guerin, A, Yu, AP et al. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am J Gastroenterol 2011;106:1670–1677.
47. Iglesias, M, Barreiro de Acosta, M, Vazquez, I et al. Psychological impact of Crohn’s disease on patients in remission: anxiety and depression risks. Rev Esp Enferm Dig 2009;101:249–257.
48. Vidal, A, Gomez-Gil, E, Sans, M et al. The impact of anxiety and depression on relapse in patients with inflammatory bowel disease. Med Clin 2009;132:298–302.
49. Vidal, A, Gomez-Gil, E, Sans, M et al. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis 2008;14:977–983.
50. Walker, JR, Ediger, JP, Graff, LA et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008;103:1989–1997.
51. Janke, KH, Klump, B, Gregor, M, Meisner, C, Haeuser, W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:272–286.
52. Persoons, P, Vermeire, S, Demyttenaere, K et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Aliment Pharmacol Ther 2005;22:101–110.
53. Mardini, HE, Kip, KE, Wilson, JW. Crohn’s disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004;49:492–497.
54. Mittermaier, C, Dejaco, C, Waldhoer, T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79–84.
55. Kurina, LM, Goldacre, MJ, Yeates, D, Gill, LE. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001;55(10):716–720.
56. Li, J, Norgard, B, Precht, DH, Olsen, J. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. Am J Gastroenterol 2004;99:1129–1133.
57. Goldsmith, DR, Rapaport, MH, Miller, BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016;21:1696–1709.
58. Margaretten, M, Julian, L, Katz, P, Yelin, E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumatol 2011;6:617–623.
59. Tyring, S, Gottlieb, A, Papp, K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29–35.
60. Hare, DL, Toukhsati, SR, Johansson, P, Jaarsma, T. Depression and cardiovascular disease: a clinical review. Eur Heart J 2014;35:1365–1372.
61. Andreoulakis, E, Hyphantis, T, Kandylis, D, Iacovides, A. Depression in diabetes mellitus: a comprehensive review. Hippokratia 2012;16:205–214.
62. Bonaccorso, S, Marino, V, Biondi, M, Grimaldi, F, Ippoliti, F, Maes, M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002;72:237–241.
63. Capuron, L, Ravaud, A, Dantzer, R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 2000;18:2143–2151.
64. Grigoleit, J-S, Kullmann, JS, Wolf, OT et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PloS One 2011;6:e28330.
65. Reichenberg, A, Yirmiya, R, Schuld, A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445–452.
66. Kent, S, Bluthe, RM, Kelley, KW, Dantzer, R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24–28.
67. Eisenberger, NI, Inagaki, TK, Mashal, NM, Irwin, MR. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 2010;24:558–563.
68. Maes, M, Berk, M, Goehler, L et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012;10:66.
69. Zhu, H, Li, YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood) 2012;237:474–480.
70. Maes, M, Kubera, M, Obuchowiczwa, E, Goehler, L, Brzeszcz, J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011;32:7–24.
71. Köhler, O, Benros, ME, Nordentoft, M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71:1381–1391.
72. Ennaifer, R, Elleuch, N, Cheikh, M et al. Risk factors of psychological disorders in inflammatory bowel disease in a tunisian survey. Results of a cross-sectional study. Tuni Med 2014;92:723–726.
73. Nahon, S, Lahmek, P, Durance, C et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2086–2091.
74. Sainsbury, A, Heatley, RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:499–508.
75. Zelinkova, Z, der Woude, C. Gender and inflammatory bowel disease. J Clin Cell Immunol 2014;5:245–253.
76. Panara, AJ, Yarur, AJ, Rieders, B et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther 2014;39:802–810.
77. Casellas, F, Lopez-Vivancos, J, Casado, A, Malagelada, JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002;11:775–781.
78. Hauser, G, Tkalčić, M, Stimac, D, Milic, S, Sincic, BM. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol 2011;35(Suppl. 2):203–207.
79. Berrill, JW, Green, JT, Hood, K, Campbell, AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013;38:44–51.
80. Norton, C, Czuber-Dochan, W, Bassett, P et al. Assessing fatigue in inflammatory bowel disease: comparison of three fatigue scales. Aliment Pharmacol Ther 2015;42:203–211.
81. Lima, FD, Ribeiro, TC, Chebli, LA et al. Mood swings in patients with Crohn’s disease: incidence and associated factors. Rev Assoc Med Bras (1992) 2012;58:481–488.
82. Hou, JK, Abraham, B, El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011;106:563–573.
83. Olendzki, BC, Silverstein, TD, Persuitte, GM, Ma, Y, Baldwin, KR, Cave, D. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J 2014;13:5.
84. Deberry, JJ, Bielefeldt, K, Davis, BM, Szigethy, EM, Hartman, DJ, Coates, MD. Abdominal pain and the neurotrophic system in ulcerative colitis. Inflamm Bowel Dis 2014;20:2330–2339.
85. Srinath, AI, Goyal, A, Zimmerman, LA et al. Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 2014;20:1329–1340.
86. Goyal, N, Rana, A, Ahlawat, A, Bijjem, KR, Kumar, P. Animal models of inflammatory bowel disease: a review. Inflammopharmacology 2014;22:219–233.
87. Okayasu, I, Hatakeyama, S, Yamada, M, Ohkusa, T, Inagaki, Y, Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694–702.
88. Gaudio, E, Taddei, G, Vetuschi, A et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci 1999;44:1458–1475.
89. Morris, GP, Beck, PL, Herridge, MS, Depew, WT, Szewczuk, MR, Wallace, JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795–803.
90. Bouma, G, Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521–533.
91. Nell, S, Suerbaum, S, Josenhans, C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010;8:564–577.
92. Mansfield, LS, Bell, JA, Wilson, DL et al. C57BL/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis. Infect Immun 2007;75:1099–1115.
93. O’Mahony, SM, Hyland, NP, Dinan, TG, Cryan, JF. Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology 2011;214:71–88.
94. Reber, SO, Birkeneder, L, Veenema, AH et al. Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms. Endocrinology 2007;148:670–682.
95. Reber, SO, Obermeier, F, Straub, RH, Veenema, AH, Neumann, ID. Aggravation of DSS-induced colitis after chronic subordinate colony (CSC) housing is partially mediated by adrenal mechanisms. Stress 2008;11:225–234.
96. Vicario, M, Guilarte, M, Alonso, C et al. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. Brain Behav Immun 2010;24:1166–1175.
97. Heydarpour, P, Rahimian, R, Fakhfouri, G et al. Behavioral despair associated with a mouse model of Crohn’s disease: role of nitric oxide pathway. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:131–141.
98. Chen, J, Winston, JH, Fu, Y et al. Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation. Am J Physiol Regul Integr Comp Physiol 2015;308:R18–R27.
99. Messaoudi, M, Desor, D, Grasmuck, V, Joyeux, M, Langlois, A, Roman, FJ. Behavioral evaluation of visceral pain in a rat model of colonic inflammation. Neuroreport 1999;10:1137–1141.
100. Painsipp, E, Herzog, H, Sperk, G, Holzer, P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br J Pharmacol 2011;163:1302–1314.
101. Lyte, M, Li, W, Opitz, N, Gaykema, RP, Goehler, LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium
. Physiol Behav 2006;89:350–357.
102. Gareau, MG, Wine, E, Rodrigues, DM et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011;60:307–317.
103. Emge, JR, Huynh, K, Miller, EN et al. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2016;310:G989–G998.
104. Bercik, P, Park, AJ, Sinclair, D et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 2011;23:1132–1139.
105. Frenois, F, Moreau, M, O’Connor, J et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007;32:516–531.
106. Mayhan, WG, Arrick, DM. eds. The Blood-Brain Barrier in Health and Disease. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. Morgan & Claypool Life Sciences, San Rafael, CA, USA, 2016.
107. Varatharaj, A, Galea, I. The blood-brain barrier in systemic inflammation. Brain Behav Immun 2017;60:1–12.
108. Hathaway, CA, Appleyard, CB, Percy, WH, Williams, JL. Experimental colitis increases blood-brain barrier permeability in rabbits. Am J Physiol 1999;276(Pt 1):G1174–G1180.
109. Hathaway, CA, Percy, WH, Williams, JL. Effects of free radicals and leukocytes on increases in blood-brain barrier permeability during colitis. Dig Dis Sci 2000;45:967–975.
110. Natah, SS, Mouihate, A, Pittman, QJ, Sharkey, KA. Disruption of the blood-brain barrier during TNBS colitis. Neurogastroenterol Motil 2005;17:433–446.
111. Sans, M, Kawachi, S, Soriano, A et al. Brain endothelial adhesion molecule expression in experimental colitis. Microcirculation 2001;8:105–114.
112. Neurath, MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329–342.
113. Leonard, B, Maes, M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764–785.
114. Riazi, K, Galic, MA, Kuzmiski, JB, Ho, W, Sharkey, KA, Pittman, QJ. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci USA 2008;105:17151–17156.
115. Medhi, B, Prakash, A, Avti, PK, Chakrabarti, A, Khanduja, KL. Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor-alpha in a rat model. J Pharm Pharmacol 2009;61:1359–1364.
116. Wang, K, Yuan, CP, Wang, W et al. Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis. World J Gastroenterol 2010;16:2252–2259.
117. Baticic, L, Detel, D, Kucic, N, Buljevic, S, Pugel, EP, Varljen, J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. J Cell Biochem 2011;112:3322–3333.
118. Alhouayek, M, Lambert, DM, Delzenne, NM, Cani, PD, Muccioli, GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011;25:2711–2721.
119. Villaran, RF, Espinosa-Oliva, AM, Sarmiento, M et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson’s disease. J Neurochem 2010;114:1687–1700.
120. Reichmann, F, Hassan, AM, Farzi, A, Jain, P, Schuligoi, R, Holzer, P. Dextran sulfate sodium-induced colitis alters stress-associated behaviour and neuropeptide gene expression in the amygdala-hippocampus network of mice. Sci Rep 2015;5:9970.
121. Becher, B, Spath, S, Goverman, J. Cytokine networks in neuroinflammation. Nat Rev Immunol 2017;17:49–59.
122. Hanisch, UK. Microglia as a source and target of cytokines. Glia 2002;40:140–155.
123. Sofroniew, MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 2014;20:160–172.
124. Dantzer, R, O’Connor, JC, Freund, GG, Johnson, RW, Kelley, KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46–56.
125. Khairova, RA, Machado-Vieira, R, Du, J, Manji, HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009;12:561–578.
126. Stellwagen, D, Malenka, RC. Synaptic scaling mediated by glial TNF-alpha. Nature 2006;440:1054–1059.
127. Miller, AH, Haroon, E, Raison, CL, Felger, JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013;30:297–306.
128. O’Connor, JC, Andre, C, Wang, Y et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009;29:4200–4209.
129. Dunn, AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000;917:608–617.
130. Miller, AH, Pariante, CM, Pearce, BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999;461:107–116.
131. Pariante, CM, Lightman, SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31:464–468.
132. Kim, YK, Na, KS, Myint, AM, Leonard, BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:277–284.
133. Kovacs, KJ. Measurement of immediate-early gene activation- c-fos and beyond. J Neuroendocrinol 2008;20:665–672.
134. Okuno, H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. Neurosci Res 2011;69:175–186.
135. Miampamba, M, Sharkey, KA. c-Fos expression in the myenteric plexus, spinal cord and brainstem following injection of formalin in the rat colonic wall. J Auton Nerv Sys 1999;77:140–151.
136. Porcher, C, Sinniger, V, Juhem, A, Mouchet, P, Bonaz, B. Neuronal activity and CRF receptor gene transcription in the brains of rats with colitis. Am J Physiol Gastrointest Liver Physiol 2004;287:G803–G814.
137. Hsiao, EY. Gastrointestinal issues in autism spectrum disorder. Harv Rev Psychiatry 2014;22:104–111.
138. Welch, MG, Welch-Horan, TB, Anwar, M, Anwar, N, Ludwig, RJ, Ruggiero, DA. Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin. J Mol Neurosci 2005;25:259–274.
139. Welch, MG, Anwar, M, Chang, CY et al. Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons. Neurogastroenterol Motil 2010;22:654–e202.
140. Goehler, LE, Gaykema, RP, Opitz, N, Reddaway, R, Badr, N, Lyte, M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni
. Brain Behav Immun 2005;19:334–344.
141. Dave, M, Higgins, PD, Middha, S, Rioux, KP. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 2012;160:246–257.
142. Frank, DN, St Amand, AL, Feldman, RA, Boedeker, EC, Harpaz, N, Pace, NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780–13785.
143. Jandhyala, SM, Talukdar, R, Subramanyam, C, Vuyyuru, H, Sasikala, M, Reddy, DN. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787–8803.
144. Jostins, L, Ripke, S, Weersma, RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119–124.
145. Nitzan, O, Elias, M, Peretz, A, Saliba, W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016;22:1078–1087.
146. Sellon, RK, Tonkonogy, S, Schultz, M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224–5231.
147. Sherwin, E, Sandhu, KV, Dinan, TG, Cryan, JF. May the force be with you: the light and dark sides of the microbiota-gut-brain axis in neuropsychiatry. CNS Drugs 2016;30:1019–1041.
148. Fuller, R. Probiotics: the scientific basis. Gut 1993;34:863–864.
149. Gibson, GR, Roberfroid, MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401–1412.
150. Mallon, P, McKay, D, Kirk, S, Gardiner, K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;4:Cd005573.
151. Rahimi, R, Nikfar, S, Rahimi, F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci 2008;53:2524–2531.
152. Casellas, F, Borruel, N, Torrejon, A et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007;25:1061–1067.
153. Bamba, T, Kanauchi, O, Andoh, A, Fujiyama, Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002;17:818–824.
154. Kanauchi, O, Suga, T, Tochihara, M et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002;37(Suppl. 14):67–72.
155. Benjamin, JL, Hedin, CR, Koutsoumpas, A et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011;60:923–929.
156. Lindsay, JO, Whelan, K, Stagg, AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 2006;55:348–355.
157. Messaoudi, M, Lalonde, R, Violle, N et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011;105:755–764.
158. Rao, AV, Bested, AC, Beaulne, TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009;1:6.
159. Schmidt, K, Cowen, PJ, Harmer, CJ, Tzortzis, G, Errington, S, Burnet, PW. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology 2015;232:1793–1801.
160. Colman, RJ, Rubin, DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014;8:1569–1581.
161. Moayyedi, P, Surette, MG, Kim, PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102–109.e6.
162. Rossen, NG, Fuentes, S, van der Spek, MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110–118.e4.
163. Kelly, JR, Borre, Y, O’Brien, C, Patterson, E et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res 2016;82:109–118.
164. Heijtz, RD, Wang, S, Anuar, F et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011;108:3047–3052.
165. Bercik, P, Park, AJ, Sinclair, D, Khoshdel, A, Lu, J, Huang, X. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterol Motil 2011;23:1132–1139.
166. Goehler, LE, Park, SM, Opitz, N, Lyte, M, Gaykema, RP.
Campylobacter jejuni infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. Brain Behav Immun 2008;22:354–366.
167. Bravo, JA, Forsythe, P, Chew, MV et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011;108:16050–16055.
168. Desbonnet, L, Garrett, L, Clarke, G, Kiely, B, Cryan, JF, Dinan, TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010;170:1179–1188.
169. Zonis, S, Pechnick, RN, Ljubimov, VA et al. Chronic intestinal inflammation alters hippocampal neurogenesis. J Neuroinflammation 2015;12:1–12.
170. Konturek, PC, Brzozowski, T, Konturek, SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011;62:591–599.
171. Deng, Q, Chen, H, Liu, Y et al. Psychological stress promotes neutrophil infiltration in colon tissue through adrenergic signaling in DSS-induced colitis model. Brain Behav Immun. 2016;30:243–254.
172. Wood, JD, Peck, OC, Tefend, KS et al. Evidence that colitis is initiated by environmental stress and sustained by fecal factors in the cotton-top tamarin (Saguinus oedipus). Dig Dis Sci 2000;45:385–393.
173. Milde, AM, Murison, R. A study of the effects of restraint stress on colitis induced by dextran sulphate sodium in singly housed rats. Integr Physiol Behav Sci 2002;37:140–150.
174. Milde, AM, Arslan, G, Overmier, JB, Berstad, A, Murison, R. An acute stressor enhances sensitivity to a chemical irritant and increases 51CrEDTA permeability of the colon in adult rats. Integr Physiol Behav Sci 2005;40:35–44.
175. Peters, S, Grunwald, N, Rummele, P et al. Chronic psychosocial stress increases the risk for inflammation-related colon carcinogenesis in male mice. Stress 2012;15:403–415.
176. Greenwood-Van Meerveld, B, Johnson, AC, Schulkin, J, Myers, DA. Long-term expression of corticotropin-releasing factor (CRF) in the paraventricular nucleus of the hypothalamus in response to an acute colonic inflammation. Brain Res 2006;1071:91–96.
177. Kojima, K, Naruse, Y, Iijima, N et al. HPA-axis responses during experimental colitis in the rat. Am J Physiol Regul Integr Comp Physiol 2002;282:R1348–R1355.
178. Agostini, A, Filippini, N, Cevolani, D et al. Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing. Inflamm Bowel Dis 2011;17:1769–1777.
179. Agostini, A, Filippini, N, Benuzzi, F et al. Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn’s disease versus healthy controls. J Behav Med 2013;36:477–487.